Comparison of different testosterone formulations discontinuation and dose spacing on hematocrit and testosterone levels in transgender individuals with erythrocytosis
Revista Brasileira de Ginecologia e Obstetrícia · 2025
DOI: 10.61622/rbgo/2025rbgo35 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Revista Brasileira de Ginecologia e Obstetrícia, 2025. Verfasst von Sérgio Henrique Pires Okano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto Ribeirão PretoSP Brazil Faculdade de Medicina de Ribeirão Preto, Universidade de Sã…. Hauptthemen laut MEDLINE: Polycythemia, Testosterone. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
This study aimed to compare the effect of Gender Affirming Hormone Therapy with Testosterone (GAHT-T) discontinuation and dose spacing on Hct, hemoglobin (Hb) and total testosterone levels in users of testosterone cypionate and testosterone undecanoate.
Methods
This retrospective cohort analyzed data collected from the medical records of trans men older than 18 years who developed erythrocytosis during GAHT-T between 2020 and 2023. Participants were divided into three groups according to formulation in use when the diagnosis of erythrocytosis occurred and analyzed according to therapeutic approaches: discontinuation of GAHT-T for 3 months or, for the testosterone cypionate fourthly users, dose spacing.
Results
A total of 49 trans men (mean age, 28.0 ± 7.8 years) were diagnosed with erythrocytosis, totalizing 104 tests. After discontinuing GAHT-T, a greater decrease in Hct, Hb and total T levels was observed in the testosterone cypionate (Cip 14 and Cip 28) users than in the testosterone undecanoate users (Und90). In Und90, discontinuation resulted in decrease of Hct and Hb levels, without difference in total T levels. Cip14 and Cip28 exhibited greater reductions in the Hct level than Und90 did with discontinuation. In Cip14, dose spacing had no effect on decreasing Hb, Hct and total T levels.
Conclusion
Discontinuation of testosterone undecanoate for 3 months in trans men undergoing GAHT-T who had developed erythrocytosis reduces hemoglobin and hematocrit levels without a significant reduction in testosterone levels. Dose spacing in fortnightly testosterone cypionate users was not effective to reduce hematocrit and hemoglobin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto Ribeirão PretoSP Brazil Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
- Faculdade de Ciências Médicas de Campinas CampinasSP Brazil Faculdade de Ciências Médicas de Campinas, Campinas, SP, Brazil.
ORCID-Profile: Sérgio Henrique Pires Okano, Silvio Antônio Franceschini, Luiz Gustavo Oliveira Brito, Lucia Alves da Silva Lara
Zitieren
APA
Okano, S. H. P., Franceschini, S. A., Brito, L. G. O., & Lara, L. A. D. S. (2025). Comparison of different testosterone formulations discontinuation and dose spacing on hematocrit and testosterone levels in transgender individuals with erythrocytosis. Revista Brasileira de Ginecologia e Obstetrícia. https://doi.org/10.61622/rbgo/2025rbgo35
Vancouver
Okano SHP, Franceschini SA, Brito LGO, Lara LADS. Comparison of different testosterone formulations discontinuation and dose spacing on hematocrit and testosterone levels in transgender individuals with erythrocytosis. Revista Brasileira de Ginecologia e Obstetrícia. 2025. doi:10.61622/rbgo/2025rbgo35
BibTeX
@article{Okano2025,
author = {Okano, Sérgio Henrique Pires and Franceschini, Silvio Antônio and Brito, Luiz Gustavo Oliveira and Lara, Lucia Alves da Silva},
title = {Comparison of different testosterone formulations discontinuation and dose spacing on hematocrit and testosterone levels in transgender individuals with erythrocytosis},
journal = {Revista Brasileira de Ginecologia e Obstetrícia},
year = {2025},
doi = {10.61622/rbgo/2025rbgo35}
}
EUVIMED